Active Procollagen II N-Terminal Propeptide (PIINP) Homo sapiens (Human) Active protein

P2NP; N-Propeptide Of Type II Procollagen; Procollagen II Amino Terminal Propeptide

Add to Cart Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 95%
  • Isoelectric Point4.2
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Procollagen II N-Terminal Propeptide (PIINP) Packages (Simulation)
  • Active Procollagen II N-Terminal Propeptide (PIINP) Packages (Simulation)
  • APA257Hu62.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Procollagen II NTerminal Propeptide (PIINP) is a specific proteolytic fragment generated during the biosynthesis of type II collagen, the major structural collagen in hyaline cartilage, intervertebral discs, and the vitreous body of the eye. During chondrocyte-mediated collagen maturation, the N-terminal propeptide is enzymatically cleaved from procollagen II and released into the extracellular matrix and biological fluids. As a direct byproduct of type II collagen synthesis, PIINP serves as a sensitive and specific biomarker for chondrocyte anabolic activity and cartilage formation. It is widely used in research and clinical assessments to evaluate cartilage turnover, monitor disease progression in osteoarthritis and rheumatoid arthritis, and reflect the integrity of cartilage metabolism. GP6, a platelet receptor, can bind to PIINP and mediate cell-matrix adhesion and downstream signaling events. Briefly, GP6 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μL were then transferred to PIINP-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-GP6 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450/630nm immediately. Measured by its binding ability in a functional ELISA. When recombinant human PIINP is lmmobilized at 2 µg/mL(100 µLwell), the concentration of GP6 that produces 50% optimal bindingresponse is found to be approximately 0.378 µg/mL.

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritisPubmed: 30830164

Recommend products